Learning Center
Plans & pricing Sign in
Sign Out

reliant pharmaceuticals llc


									                                             Richard F. Pops
                                           Chief Executive Officer
                                               Alkermes, Inc.

Alkermes, Inc., is applying sophisticated drug delivery technologies, product development and manufacturing
capabilities to the development of an expanding portfolio of pharmaceutical products. Alkermes has several areas of
focus, including: (i) controlled, sustained-release of injectable drugs lasting several days to several weeks, utilizing
its ProLease® and Medisorb® technologies and (ii) pulmonary delivery of small molecules and protein and peptide-
based drugs utilizing its Advanced Inhalation Research (AIR™) technology.


Richard Pops has been Chief Executive Officer of Alkermes since February 1991. A native of Los Angeles,
California, Richard received a B.A., in Economics from Stanford University in 1983. From 1984 to 1991, he was
employed by PaineWebber, Inc., in New York as Vice President of PaineWebber Development Corporation,
providing product development financing for the country’s leading biotechnology and high-technology companies.


Under Richard's leadership, Alkermes has grown from a privately held company with 25 employees to a publicly
traded, leading specialty pharmaceutical company (NASDAQ:ALKS) with more than 400 employees in the United
States. The company has raised over $600 million to support the research and development of its product candidates
and has consummated important strategic alliances with major pharmaceutical companies, including: Serono, S.A.,
Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline and Janssen Pharmaceutica, Inc..

The company is recognized as a world leader in the development of injectable, sustained-release formulations of
drugs through its ProLease® and Medisorb® technologies. In December 1999, Alkermes and its partner,
Genentech, announced the FDA approval of Nutropin Depot™ (rhGH) for the treatment of pediatric growth
hormone deficiency, using Alkermes’ ProLease injectable, sustained-release drug delivery system. Alkermes and
Janssen Pharmaceutica are developing Risperdal Consta™, an injectable, sustained-release formulation of Janssen’s
anti-psychotic drug RISPERDAL®. Risperdal Consta has completed Phase III clinical trials and is pending
Regulatory approval. Alkermes has also established a significant presence in the field of pulmonary drug delivery.
The pulmonary drug delivery system, known as AIR, offers a unique, proprietary delivery system for optimized drug
delivery to the lungs. In the past year, Alkermes has entered into important pulmonary drug delivery collaborations
with Eli Lilly and Company and GlaxoSmithKline.

Outside Directorships

Mr. Pops currently serves on the Board of Directors of: Alkermes, Inc.; Neurocrine Biosciences, Inc.; Reliant
Pharmaceuticals, LLC; Genomics Collaborative, Inc.; CombinatoRx, Inc.; Expressive Constructs, Inc.; the
Biotechnology Industry Organization (BIO); the Massachusetts Biotechnology Council (MBC); Harvard Medical
School Board of Fellows and The Fessenden School Board of Trustees. He also serves as Chair for the Harvard
Medical School Advisory Council for Biological Chemistry & Molecular Pharmacology (BCMP) and is an
Advisory Board Member of The Cloud Foundation and Polaris Venture Partners.

To top